Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

Nienke M. Scheltema, Xynthia M. Kavelaars, Kentigern Thorburn, Marije P. Hennus, Job B. van Woensel, Cornelis K. van der Ent, Jose A. M. Borghans, Louis J. Bont, Julia Drylewicz*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

5 Downloads (Pure)

Abstract

Background: 

Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.

Methods: 

We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.

Results: 

Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.

Conclusions: 

Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants. (C) 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.

Original languageEnglish
Pages (from-to)4693-4700
JournalVaccine
Volume36
Issue number31
DOIs
Publication statusPublished - 2018

Keywords

  • RSV
  • Maternal vaccination
  • Mathematical model
  • Life-threatening infections
  • Infant mortality
  • ANTIBODY TRANSFER
  • YOUNG-CHILDREN
  • NEUTRALIZING ANTIBODIES
  • INFLUENZA IMMUNIZATION
  • CHILDBEARING AGE
  • HIGH-RISK
  • PERTUSSIS
  • MORTALITY
  • DISEASE

Cite this

Scheltema, N. M., Kavelaars, X. M., Thorburn, K., Hennus, M. P., van Woensel, J. B., van der Ent, C. K., ... Drylewicz, J. (2018). Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. Vaccine, 36(31), 4693-4700. https://doi.org/10.1016/j.vaccine.2018.06.021
Scheltema, Nienke M. ; Kavelaars, Xynthia M. ; Thorburn, Kentigern ; Hennus, Marije P. ; van Woensel, Job B. ; van der Ent, Cornelis K. ; Borghans, Jose A. M. ; Bont, Louis J. ; Drylewicz, Julia. / Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. In: Vaccine. 2018 ; Vol. 36, No. 31. pp. 4693-4700.
@article{0307b5adc70c41e8940988d9217ce79f,
title = "Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy",
abstract = "Background: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75{\%} of RSV-related PICU admissions in the United Kingdom and 76-87{\%} in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48{\%} of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants. (C) 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.",
keywords = "RSV, Maternal vaccination, Mathematical model, Life-threatening infections, Infant mortality, ANTIBODY TRANSFER, YOUNG-CHILDREN, NEUTRALIZING ANTIBODIES, INFLUENZA IMMUNIZATION, CHILDBEARING AGE, HIGH-RISK, PERTUSSIS, MORTALITY, DISEASE",
author = "Scheltema, {Nienke M.} and Kavelaars, {Xynthia M.} and Kentigern Thorburn and Hennus, {Marije P.} and {van Woensel}, {Job B.} and {van der Ent}, {Cornelis K.} and Borghans, {Jose A. M.} and Bont, {Louis J.} and Julia Drylewicz",
year = "2018",
doi = "10.1016/j.vaccine.2018.06.021",
language = "English",
volume = "36",
pages = "4693--4700",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "31",

}

Scheltema, NM, Kavelaars, XM, Thorburn, K, Hennus, MP, van Woensel, JB, van der Ent, CK, Borghans, JAM, Bont, LJ & Drylewicz, J 2018, 'Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy', Vaccine, vol. 36, no. 31, pp. 4693-4700. https://doi.org/10.1016/j.vaccine.2018.06.021

Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. / Scheltema, Nienke M.; Kavelaars, Xynthia M.; Thorburn, Kentigern; Hennus, Marije P.; van Woensel, Job B.; van der Ent, Cornelis K.; Borghans, Jose A. M.; Bont, Louis J.; Drylewicz, Julia.

In: Vaccine, Vol. 36, No. 31, 2018, p. 4693-4700.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

AU - Scheltema, Nienke M.

AU - Kavelaars, Xynthia M.

AU - Thorburn, Kentigern

AU - Hennus, Marije P.

AU - van Woensel, Job B.

AU - van der Ent, Cornelis K.

AU - Borghans, Jose A. M.

AU - Bont, Louis J.

AU - Drylewicz, Julia

PY - 2018

Y1 - 2018

N2 - Background: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants. (C) 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.

AB - Background: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants. (C) 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.

KW - RSV

KW - Maternal vaccination

KW - Mathematical model

KW - Life-threatening infections

KW - Infant mortality

KW - ANTIBODY TRANSFER

KW - YOUNG-CHILDREN

KW - NEUTRALIZING ANTIBODIES

KW - INFLUENZA IMMUNIZATION

KW - CHILDBEARING AGE

KW - HIGH-RISK

KW - PERTUSSIS

KW - MORTALITY

KW - DISEASE

U2 - 10.1016/j.vaccine.2018.06.021

DO - 10.1016/j.vaccine.2018.06.021

M3 - Article

VL - 36

SP - 4693

EP - 4700

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 31

ER -